Sonesitatug Vedotin Demonstrated a Statistically Significant and Highly Clinically Meaningful Improvement in Overall Survival in 2nd and Later-Line CLDN18.2-Positive Advanced Gastric/GEJ Cancers
July 28, 2026
July 28, 2026
WILMINGTON, Delaware, July 28 -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
Results provide opportunity to expand CLDN18.2 positivity to 25% expression, representing approximately 60% of patients in this setting
C . . .
* * *
Sonesitatug vedotin demonstrated a statistically significant and highly clinically meaningful improvement in overall survival in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers
Results provide opportunity to expand CLDN18.2 positivity to 25% expression, representing approximately 60% of patients in this setting
C . . .